Skip to main content
Verified Statutory Healthcare Resource — Indian Pharmacopoeia (IP) / CDSCO / PMBJP Jan Aushadhi Standards
Acidity & Digestion 5 min read • Last Updated: September 2026

Aciloc 150 (Ranitidine) vs Pantoprazole: Is Aciloc Safe in India?

Clinical status of Aciloc 150 (Ranitidine H2 blocker) in India: NDMA impurity findings, CDSCO regulatory updates, and safer PPI alternatives.

Statutory Medical Disclaimer & Emergency Safety Notice The pharmacological and therapeutic data presented in this educational guide is synthesized exclusively for public health literacy, academic reference, and educational purposes in conformity with the Indian Pharmacopoeia (IP 2022) and guidelines established by the Central Drugs Standard Control Organisation (CDSCO). This content does not constitute medical diagnosis, formal physician opinion, or individualized therapeutic instruction. Under the Drugs and Cosmetics Act, 1940 and the National Medical Commission (Professional Conduct) Regulations, Schedule H, H1, and X pharmaceutical formulations must be prescribed and monitored by a registered medical practitioner (RMP). Patients must not initiate, alter, or terminate any therapeutic drug regimen without formal clinical evaluation by their treating physician or a licensed healthcare professional. For acute medical emergencies, dial 112 / 108 (India) immediately.
🩺 Quick Clinical Answer

Aciloc contains Ranitidine (150mg), an H2-receptor antagonist that blocks histamine-stimulated stomach acid. While international regulators recalled certain ranitidine brands due to trace NDMA impurities under high-temperature storage, the CDSCO allowed batch-verified formulations in India. However, physicians now predominantly prescribe Famotidine or Pantoprazole.

1. Mechanism of H2 Blockers vs PPIs

Ranitidine blocks histamine H2 receptors on parietal cells, whereas PPIs directly block the final common pathway (H+/K+ ATPase enzyme). H2 blockers work faster (within 30-45 mins) but exhibit tolerance (tachyphylaxis) after 2 weeks of continuous use.

2. The NDMA Impurity Context

N-nitrosodimethylamine (NDMA) is an environmental contaminant classified as a probable human carcinogen. Batches that degrade over time in warm conditions generated elevated NDMA levels, prompting strict manufacturing controls.

3. Safer Modern Alternatives

Famotidine 20mg/40mg (available at Jan Aushadhi for ₹3.50/strip) is a stable H2 blocker without NDMA degradation issues. Pantoprazole 40mg remains the primary choice for healing erosive esophagitis.

PMBJP Jan Aushadhi Price Transparency

Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison

Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.

Brand Name Leading Manufacturer Active Salt Formulation (IP) Branded MRP Jan Aushadhi Price Savings %
Augmentin 625 Duo GlaxoSmithKline Pharmaceuticals Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP ₹220.00 ₹58.00 74%
Dolo 650 Micro Labs Ltd Paracetamol (Acetaminophen) 650mg IP ₹34.00 ₹5.50 84%
Pantocid 40 Sun Pharmaceutical Industries Pantoprazole Sodium 40mg IP (Gastro-resistant) ₹155.00 ₹8.00 95%
Azithral 500 Alembic Pharmaceuticals Azithromycin Dihydrate 500mg IP ₹132.00 ₹24.00 82%
Glycomet 500 USV Private Limited Metformin Hydrochloride 500mg IP ₹24.00 ₹4.50 81%
Shelcal 500 Torrent Pharmaceuticals Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP ₹134.00 ₹16.00 88%
Telma 40 Glenmark Pharmaceuticals Telmisartan 40mg IP ₹92.00 ₹7.50 92%
Montair-LC Cipla Ltd Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP ₹210.00 ₹18.00 91%
Combined 8-Drug Essential Therapy Basket Total: ₹1,001.00 ₹141.00 85.9% Net Savings
Additional high-volume Indian medicines bioequivalent generic savings: Atorva 10 (Atorvastatin 10mg: Branded ₹110.00 vs Jan Aushadhi ₹12.00, 89% savings), Allegra 120 (Fexofenadine 120mg: Branded ₹215.00 vs Jan Aushadhi ₹32.00, 85% savings). Official Portal: PMBJP National Formulary (janaushadhi.gov.in) →

Frequently Asked Questions (Clinical & Regulatory)

Q1: Can Aciloc be taken during pregnancy for heartburn?

Famotidine is now clinically favored over ranitidine during pregnancy due to higher purity standards, under doctor advice.

Q2: Can I take Aciloc 150 at night?

Yes, H2 blockers are particularly effective at suppressing nocturnal acid breakthrough when taken at bedtime.

Q3: What is the optimal timing for taking Proton Pump Inhibitors (Pantoprazole, Omeprazole)?

Proton Pump Inhibitors (PPIs) must be administered 30 to 60 minutes before the morning meal with plain water. PPIs are prodrugs that require actively secreting H+/K+ ATPase proton pumps—stimulated by food anticipation—to achieve irreversible covalent enzyme suppression.

Q4: Are PMBJP generic PPIs bioequivalent to branded antacids like Pantocid 40 or Omez?

Yes. PMBJP Jan Aushadhi gastro-resistant pantoprazole and omeprazole tablets are formulated in WHO-GMP certified facilities with enteric polymers that protect the active drug from gastric acid degradation, matching innovator dissolution and bioavailability profiles at up to 95% patient savings.

Q5: Can antacid syrups be taken simultaneously with oral antibiotics or thyroid tablets?

No. Antacid suspensions containing aluminum hydroxide, magnesium hydroxide, or calcium carbonate chelate antibiotics (ciprofloxacin, doxycycline) and levothyroxine in the gastrointestinal tract, reducing systemic drug absorption by 50% to 75%. Maintain a strict 2-hour interval.

MediMatch AI Clinical Pharmacology Review Board
Clinically reviewed by Dr. Vikram Anand, MBBS, MD (Clinical Pharmacology), Dr. Aditi Sharma, MD Pharmacology & Dr. Rajesh Nair, PharmD, RPh

This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.

Official Statutory References: Indian Pharmacopoeia Commission (ipc.gov.in) → PMBJP Jan Aushadhi Portal (janaushadhi.gov.in) → CDSCO Health & Family Welfare (cdsco.gov.in) →
Digital Personal Data Protection (DPDP) Act, 2023 Statutory Health Privacy Disclosure

Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.